Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.47 |
| ▸ | CKS1B | P61024 | 2/20 | 0.46 |
| ▸ | SKP1 | P63208 | 2/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26669527 | 0.90 | GPR119 (0.47) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL25256362 | 0.84 | GPR119 (0.49) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL5128070 | 0.80 | GPR119 (0.49) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL3561037 | 0.78 | CKS1B (0.65) | GPR119CKS1BSKP1SKP2SMARCA2 | |
| SCHEMBL2227063 | 0.78 | GPR119 (0.56) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL2798741 | 0.78 | KIT (0.51) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL10319563 | 0.78 | GPR119 (0.53) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL2422161 | 0.77 | KIT (0.50) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL30417388 | 0.77 | KIT (0.50) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL2796054 | 0.77 | KIT (0.53) | GPR119CKS1BSKP1SKP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-116917279-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | GPR119 1014/4885CKS1B 394/4885SKP1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.